(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035823 A2

(51) International Patent Classification[7]: C12Q 1/68

(21) International Application Number: PCT/EP2003/011478

(22) International Filing Date: 16 October 2003 (16.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02023272.4 17 October 2002 (17.10.2002) EP
60/418,721 17 October 2002 (17.10.2002) US

(71) Applicant *(for all designated States except US)*: **EVOTEC NEUROSCIENCES GMBH** [DE/DE]; Schnackenburgallee 114, 22525 Hamburg (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **VON DER KAMMER, Heinz** [DE/DE]; Verbindungsstr. 6d, 22607 Hamburg (DE). **POHLNER, Johannes** [DE/DE]; Quittenweg 11, 22175 Hamburg (DE).

(74) Agents: **MEYERS, Hans-Wilhelm** et al.; Von Kreisler Selting Werner, P.O. Box 10 22 41, 50426 Cologne (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTIC AND THERAPEUTIC USE OF ENSADIN-0625 GENE AND PROTEIN FOR NEURODEGENERATIVE DISEASES



(57) Abstract: The present invention discloses the differential expression of a gene coding for Ensadin-0625 in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the Ensadin-0625 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

WO 2004/035823 A2

DIAGNOSTIC AND THERAPEUTIC USE OF ENSADIN-0625 GENE AND PROTEIN FOR NEURODEGENERATIVE DISEASES

The present invention relates to methods of diagnosing, prognosticating, and monitoring the progression of neurodegenerative diseases in a subject. Furthermore, methods of therapy control and screening for modulating agents of neurodegenerative diseases are provided. The invention also discloses pharmaceutical compositions, kits, and recombinant animal models.

Neurodegenerative diseases, in particular Alzheimer's disease (AD), have a strongly debilitating impact on a patient's life. Furthermore, these diseases constitute an enormous health, social, and economic burden. AD is the most common neurodegenerative disease, accounting for about 70% of all dementia cases, and it is probably the most devastating age-related neurodegenerative condition affecting about 10% of the population over 65 years of age and up to 45% over age 85 (for a recent review see Vickers et al., *Progress in Neurobiology* 2000, 60: 139-165). Presently, this amounts to an estimated 12 million cases in the US, Europe, and Japan. This situation will inevitably worsen with the demographic increase in the number of old people ("aging of the baby boomers") in developed countries. The neuropathological hallmarks that occur in the brains of individuals with AD are senile plaques, composed of amyloid-β protein, and profound cytoskeletal changes coinciding with the appearance of abnormal filamentous structures and the formation of neurofibrillary tangles.

The amyloid-β (Aβ) protein evolves from the cleavage of the amyloid precursor protein (APP) by different kinds of proteases. The cleavage by the β/γ-secretase leads to the formation of Aβ peptides of different lengths, typically a short more soluble and slow aggregating peptide consisting of 40 amino acids and a longer 42 amino acid peptide, which rapidly aggregates outside the cells, forming the characteristic amyloid plaques (Selkoe, *Physiological Rev* 2001, 81: 741-66; Greenfield et al., *Frontiers Bioscience* 2000, 5: D72-83). Two types of plaques, diffuse plaques and neuritic plaques, can be detected in the brain of AD patients, the latter ones being the classical, most prevalent type. They are primarily found in the cerebral cortex and hippocampus. The neuritic plaques have a diameter of 50µm to 200µm and are composed of insoluble fibrillar amyloids, fragments of dead

CONFIRMATION COPY

neurons, of microglia and astrocytes, and other components such as neurotransmitters, apolipoprotein E, glycosaminoglycans, α1-antichymotrypsin and others. The generation of toxic Aβ deposits in the brain starts very early in the course of AD, and it is discussed to be a key player for the subsequent destructive processes leading to AD pathology. The other pathological hallmarks of AD are neurofibrillary tangles (NFTs) and abnormal neurites, described as neuropil threads (Braak and Braak, *Acta Neuropathol* 1991, 82: 239-259). NFTs emerge inside neurons and consist of chemically altered tau, which forms paired helical filaments twisted around each other. Along the formation of NFTs, a loss of neurons can be observed. It is discussed that said neuron loss may be due to a damaged microtubule-associated transport system (Johnson and Jenkins, *J Alzheimers Dis* 1996, 1: 38-58; Johnson and Hartigan, *J Alzheimers Dis* 1999, 1: 329-351). The appearance of neurofibrillary tangles and their increasing number correlates well with the clinical severity of AD (Schmitt et al., *Neurology* 2000, 55: 370-376).

AD is a progressive disease that is associated with early deficits in memory formation and ultimately leads to the complete erosion of higher cognitive function. The cognitive disturbances include among other things memory impairment, aphasia, agnosia and the loss of executive functioning. A characteristic feature of the pathogenesis of AD is the selective vulnerability of particular brain regions and subpopulations of nerve cells to the degenerative process. Specifically, the temporal lobe region and the hippocampus are affected early and more severely during the progression of the disease. On the other hand, neurons within the frontal cortex, occipital cortex, and the cerebellum remain largely intact and are protected from neurodegeneration (Terry et al., *Annals of Neurology* 1981, 10: 184-92).

The age of onset of AD may vary within a range of 50 years, with early-onset AD occurring in people younger than 65 years of age, and late-onset of AD occurring in those older than 65 years. About 10% of all AD cases suffer from early-onset AD, with only 1-2% being familial, inherited cases.

Currently, there is no cure for AD, nor is there an effective treatment to halt the progression of AD or even to diagnose AD ante-mortem with high probability. Several risk factors have been identified that predispose an individual to develop AD, among them most prominently the epsilon 4 allele of the three different existing alleles (epsilon 2, 3, and 4) of the apolipoprotein E gene (ApoE) (Strittmatter et al., *Proc Natl Acad Sci USA* 1993, 90: 1977-81; Roses, *Ann NY Acad Sci* 1998, 855: 738-43). The polymorphic plasmaprotein ApoE plays a role in the intercellular cholesterol and phospholipid transport by binding low-density lipoprotein receptors,

and it seems to play a role in neurite growth and regeneration. Efforts to detect further susceptibility genes and disease-linked polymorphisms, lead to the assumption that specific regions and genes on human chromosomes 10 and 12 may be associated with late-onset AD (Myers et al., *Science* 2000, 290: 2304-5; Bertram et al., *Science* 2000, 290: 2303; Scott et al., *Am J Hum Genet* 2000, 66: 922-32).
Although there are rare examples of early-onset AD which have been attributed to genetic defects in the genes for amyloid precursor protein (APP) on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1, the prevalent form of late-onset sporadic AD is of hitherto unknown etiologic origin. The mutations found to date account for only half of the familial AD cases, which is less than 2% of all AD patients. The late onset and complex pathogenesis of neurodegenerative disorders pose a formidable challenge to the development of therapeutic and diagnostic agents. It is crucial to expand the pool of potential drug targets and diagnostic markers. It is therefore an object of the present invention to provide insight into the pathogenesis of neurological diseases and to provide methods, materials, agents, compositions, and animal models which are suited inter alia for the diagnosis and development of a treatment of these diseases. This object has been solved by the features of the independent claims. The subclaims define preferred embodiments of the present invention.

The present invention is based on the detection and differential expression of a gene coding for Ensadin-0625 in human Alzheimer's disease brain samples. Originally, the gene coding for Ensadin-0625 was isolated and cloned in an attempt to identify susceptibility genes for hereditary prostate cancer (HPC1) and for hereditary hyperparathyroidism-jaw tumor syndrome (HPT-JT). Sood and coworkers accomplished an entire transcript map of the candidate region for the HPC1 locus on chromosome 1q25. The 59 transcripts found in this region represent 22 already known genes and 37 EST (expressed sequence tag) clusters. Further analysis of these ESTs revealed full-length transcripts of 13 novel genes. One of the mRNAs found was named C1orf15 (Genbank accession number AF288395; Sood et al., *Genomics* 2001, 73:211-222). The human cDNA of Ensadin-0625 is homologous to the nucleotide sequence of said C1orf15 mRNA (AF288395) and to the nucleotide sequence of the KIAA0479 clone (Genbank accession number AB007948).
The human Ensadin-0625 gene, represented by 5691 bp of the C1orf15 mRNA (AF288395), harbors a predicted open reading frame coding for a protein of 307 amino acids in length (SEQ ID NO. 1) with an approximate molecular weight of

about 34.5 kDa. The predicted protein is identical to the protein product of Genbank ID number Q9BZQ4 (EMBL protein ID: AAG60615.1). Human Ensadin-0625 protein shows some homology on the amino acid sequence level (~ 42% identity) to the protein product of a human nicotinamide mononucleotide adenylyl transferase (NMNAT) (Genbank ID number Q9HAN9). Based on its similarities with the nuclear enzyme NMNAT-1, the KIAA0479 protein was characterized as a member of the NMNAT family and was denoted NMNAT-2 (Raffaelli et al., *Biochem. Biophys. Res. Com.* 2002, 297: 835-840). No homology or similarity to any other known proteins have been identified to date. On the basis of the transcript mapping studies of the HPC1 candidate region, the Ensadin-0625 gene could be located on human chromosome 1q25. Characterization of the expression profile using Northern blot analysis and a probe of the transcript derived from the KIAA0479 sequence revealed a weak hybridization signal in the range of 6.5 kb in testis and placenta and a very strong expression signal in brain (Sood et al., *Genomics* 2001, 73: 211-222). Because of the prominent brain expression and the fact that the KIAA0479 sequence was identified from a brain cDNA library, one can assume that the expression of KIAA0479, and thus Ensadin-0625, is largely brain-specific. As disclosed in the present invention, the Ensadin-0625 gene was found to be expressed in human adult brain.

The present invention discloses a dysregulation of Ensadin-0625 gene expression on the transcriptional level in the temporal cortex region relative to the frontal cortex region in brain samples taken from AD patients. No such dysregulation is observed in samples derived from age-matched, healthy controls. To date, no experiments have been described that demonstrate a relationship between the dysregulation of Ensadin-0625 gene expression and the pathology of neurodegenerative diseases, in particular AD. Likewise, no mutations in Ensadin-0625 have been described to be associated with said diseases. Linking the Ensadin-0625 gene to such diseases, as disclosed in the instant invention, offers new ways, inter alia, for the diagnosis and treatment of said diseases.

The singular forms "a", "an", and "the" as used herein and in the claims include plural reference unless the context dictates otherwise. For example, "a cell" means as well a plurality of cells, and so forth. The term "and/or" as used in the present specification and in the claims implies that the phrases before and after this term are to be considered either as alternatives or in combination. For instance, the

wording "determination of a level and/or an activity" means that either only a level, or only an activity, or both a level and an activity are determined. The term "level" as used herein is meant to comprise a gage of, or a measure of the amount of, or a concentration of a transcription product, for instance an mRNA, or a translation product, for instance a protein or polypeptide. The term "activity" as used herein shall be understood as a measure for the ability of a transcription product or a translation product to produce a biological effect or a measure for a level of biologically active molecules. The term "activity" also refers to enzymatic activity. The terms "level" and/or "activity" as used herein further refer to gene expression levels or gene activity. Gene expression can be defined as the utilization of the information contained in a gene by transcription and translation leading to the production of a gene product. "Dysregulation" shall mean an upregulation or downregulation of gene expression. A gene product comprises either RNA or protein and is the result of expression of a gene. The amount of a gene product can be used to measure how active a gene is. The term "gene" as used in the present specification and in the claims comprises both coding regions (exons) as well as non-coding regions (e.g. non-coding regulatory elements such as promoters or enhancers, introns, leader and trailer sequences). The term "ORF" is an acronym for "open reading frame" and refers to a nucleic acid sequence that does not possess a stop codon in at least one reading frame and therefore can potentially be translated into a sequence of amino acids. "Regulatory elements" shall comprise inducible and non-inducible promoters, enhancers, operators, and other elements that drive and regulate gene expression. The term "fragment" as used herein is meant to comprise e.g. an alternatively spliced, or truncated, or otherwise cleaved transcription product or translation product. The term "derivative" as used herein refers to a mutant, or an RNA-edited, or a chemically modified, or otherwise altered transcription product, or to a mutant, or chemically modified, or otherwise altered translation product. For instance, a "derivative" may be generated by processes such as altered phosphorylation, or glycosylation, or acetylation, or lipidation, or by altered signal peptide cleavage or other types of maturation cleavage. These processes may occur post-translationally. The term "modulator" as used in the present invention and in the claims refers to a molecule capable of changing or altering the level and/or the activity of a gene, or a transcription product of a gene, or a translation product of a gene. Preferably, a "modulator" is capable of changing or altering the biological activity of a transcription product or a translation product of a gene. Said modulation, for instance, may be an increase or a decrease in enzyme activity, a

change in binding characteristics, or any other change or alteration in the biological, functional, or immunological properties of said translation product of a gene. The terms "agent", "reagent", or "compound" refer to any substance, chemical, composition or extract that have a positive or negative biological effect on a cell, tissue, body fluid, or within the context of any biological system, or any assay system examined. They can be agonists, antagonists, partial agonists or inverse agonists of a target. Such agents, reagents, or compounds may be nucleic acids, natural or synthetic peptides or protein complexes, or fusion proteins. They may also be antibodies, organic or anorganic molecules or compositions, small molecules, drugs and any combinations of any of said agents above. They may be used for testing, for diagnostic or for therapeutic purposes. The terms "oligonucleotide primer" or "primer" refer to short nucleic acid sequences which can anneal to a given target polynucleotide by hybridization of the complementary base pairs and can be extended by a polymerase. They may be chosen to be specific to a particular sequence or they may be randomly selected, e.g. they will prime all possible sequences in a mix. The length of primers used herein may vary from 10 nucleotides to 80 nucleotides. "Probes" are short nucleic acid sequences of the nucleic acid sequences described and disclosed herein or sequences complementary therewith. They may comprise full length sequences, or fragments, derivatives, isoforms, or variants of a given sequence. The identification of hybridization complexes between a "probe" and an assayed sample allows the detection of the presence of other similar sequences within that sample. As used herein, "homolog or homology" is a term used in the art to describe the relatedness of a nucleotide or peptide sequence to another nucleotide or peptide sequence, which is determined by the degree of identity and/or similarity between said sequences compared. The term "variant" as used herein refers to any polypeptide or protein, in reference to polypeptides and proteins disclosed in the present invention, in which one or more amino acids are added and/or substituted and/or deleted and/or inserted at the N-terminus, and/or the C-terminus, and/or within the native amino acid sequences of the native polypeptides or proteins of the present invention. Furthermore, the term "variant" shall include any shorter or longer version of a polypeptide or protein. "Variants" shall also comprise a sequence that has at least about 80% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% sequence identity with the amino acid sequences of Ensadin-0625, SEQ ID NO. 1. "Variants" of a protein molecule of Ensadin-0625, SEQ ID NO. 1, include, for example, proteins with conservative amino acid substitutions in highly conservative

regions. "Proteins and polypeptides" of the present invention include variants, fragments and chemical derivatives of the protein comprising the amino acid sequences of Ensadin-0625, SEQ ID NO. 1. They can include proteins and polypeptides which can be isolated from nature or be produced by recombinant and/or synthetic means. Native proteins or polypeptides refer to naturally-occurring truncated or secreted forms, naturally occurring variant forms (e.g. splice-variants) and naturally occurring allelic variants. The term "isolated" as used herein is considered to refer to molecules that are removed from their natural environment, i.e. isolated from a cell or from a living organism in which they normally occur, and that are separated or essentially purified from the coexisting components with which they are found to be associated in nature. This notion further means that the sequences encoding such molecules can be linked by the hand of man to polynucleotides, to which they are not linked in their natural state, and that such molecules can be produced by recombinant and/or synthetic means. Even if for said purposes those sequences may be introduced into living or non-living organisms by methods known to those skilled in the art, and even if those sequences are still present in said organisms, they are still considered to be isolated. In the present invention, the terms "risk", "susceptibility", and "predisposition" are tantamount and are used with respect to the probability of developing a neurodegenerative disease, preferably Alzheimer's disease. The term 'AD' shall mean Alzheimer's disease. "AD-type neuropathology" as used herein refers to neuropathological, neurophysiological, histopathological and clinical hallmarks as described in the instant invention and as commonly known from state-of-the-art literature (see: Iqbal, Swaab, Winblad and Wisniewski, *Alzheimer`s Disease and Related Disorders (Etiology, Pathogenesis and Therapeutics)*, Wiley & Sons, New York, Weinheim, Toronto, 1999; Scinto and Daffner, *Early Diagnosis of Alzheimer`s Disease*, Humana Press, Totowa, New Jersey, 2000; Mayeux and Christen, *Epidemiology of Alzheimer`s Disease: From Gene to Prevention*, Springer Press, Berlin, Heidelberg, New York, 1999; Younkin, Tanzi and Christen, *Presenilins and Alzheimer`s Disease*, Springer Press, Berlin, Heidelberg, New York, 1998).

Neurodegenerative diseases or disorders according to the present invention comprise Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro-vascular dementia, multiple system atrophy, argyrophilic grain dementia and other tauopathies, and mild-cognitive impairment. Further conditions involving neurodegenerative processes are,

for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.

In one aspect, the invention features a method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease. The method comprises: determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for Ensadin-0625, and/or of (ii) a translation product of a gene coding for Ensadin-0625, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject and comparing said level, and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

The invention also relates to the construction and the use of primers and probes which are unique to the nucleic acid sequences, or fragments, or variants thereof, as disclosed in the present invention. The oligonucleotide primers and/or probes can be labeled specifically with fluorescent, bioluminescent, magnetic, or radioactive substances. The invention further relates to the detection and the production of said nucleic acid sequences, or fragments and variants thereof, using said specific oligonucleotide primers in appropriate combinations. PCR-analysis, a method well known to those skilled in the art, can be performed with said primer combinations to amplify said gene specific nucleic acid sequences from a sample containing nucleic acids. Such sample may be derived either from healthy or diseased subjects. Whether an amplification results in a specific nucleic acid product or not, and whether a fragment of different length can be obtained or not, may be indicative for a neurodegenerative disease, in particular Alzheimer's disease. Thus, the invention provides nucleic acid sequences, oligonucleotide primers, and probes of at least 10 bases in length up to the entire coding and gene sequences, useful for the detection of gene mutations and single nucleotide polymorphisms in a given sample comprising nucleic acid sequences to be examined, which may be associated with neurodegenerative diseases, in particular Alzheimer's disease. This feature has utility for developing rapid DNA-based diagnostic tests, preferably also in the format of a kit.

In a further aspect, the invention features a method of monitoring the progression of a neurodegenerative disease in a subject. A level, or an activity, or both said level and said activity, of (i) a transcription product of a gene coding for Ensadin-0625, and/or of (ii) a translation product of a gene coding for Ensadin-0625, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject is determined. Said level and/or said activity is compared to a reference value representing a known disease or health status. Thereby, the progression of said neurodegenerative disease in said subject is monitored.

In still a further aspect, the invention features a method of evaluating a treatment for a neurodegenerative disease, comprising determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for Ensadin-0625, and/or of (ii) a translation product of a gene coding for Ensadin-0625, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample obtained from a subject being treated for said disease. Said level, or said activity, or both said level and said activity are compared to a reference value representing a known disease or health status, thereby evaluating the treatment for said neurodegenerative disease.

In a preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said gene coding for Ensadin-0625 protein is the gene coding for the protein of Genbank accession number Q9BZQ4, deduced from the mRNA of C1orf15 (NCBI Genbank accession number: AF288395).

In a further preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said neurodegenerative disease or disorder is Alzheimer's disease, and said subjects suffer from Alzheimer's disease.

The present invention discloses the detection and differential expression and dysregulation of a gene coding for Ensadin-0625 in specific brain regions of AD patients. Consequently, the Ensadin-0625 gene and its corresponding transcription and/or translation products may have a causative role in the regional selective neuronal degeneration typically observed in AD. Alternatively, Ensadin-0625 may confer a neuroprotective function to the remaining surviving nerve cells. Based on

these disclosures, the present invention has utility for the diagnostic evaluation and prognosis as well as for the identification of a predisposition to a neurodegenerative disease, in particular AD. Furthermore, the present invention provides methods for the diagnostic monitoring of patients undergoing treatment for such a disease.

It is preferred that the sample to be analyzed and determined is selected from the group comprising brain tissue or other tissues or body cells. The sample can also comprise cerebrospinal fluid or other body fluids including saliva, urine, blood, serum plasma, or mucus. Preferably, the methods of diagnosis, prognosis, monitoring the progression or evaluating a treatment for a neurodegenerative disease, according to the instant invention, can be practiced *ex corpore*, and such methods preferably relate to samples, for instance, body fluids or cells, removed, collected, or isolated from a subject or patient.

In further preferred embodiments, said reference value is that of a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for Ensadin-0625, and/or of (ii) a translation product of a gene coding for Ensadin-0625, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from a subject not suffering from said neurodegenerative disease.

In preferred embodiments, an alteration in the level and/or activity of a transcription product of a gene coding for Ensadin-0625 and/or of a translation product of a gene coding for Ensadin-0625 and/or of a fragment, or derivative, or variant thereof in a sample cell, or tissue, or body fluid from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of becoming diseased with a neurodegenerative disease, particularly AD.

In preferred embodiments, measurement of the level of transcription products of an Ensadin-0625 gene is performed in a sample from a subject using a quantitative PCR-analysis with primer combinations to amplify said gene specific sequences from cDNA obtained by reverse transcription of RNA extracted from a sample of a subject. A Northern blot with probes specific for said gene can also be applied. It might further be preferred to measure transcription products by means of chip-based microarray technologies. These techniques are known to those of ordinary skill in the art (see e.g. Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*,

Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001; Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000). An example of an immunoassay is the detection and measurement of enzyme activity as disclosed and described in the patent application WO 02/14543.

Furthermore, a level and/or an activity of a translation product of an Ensadin-0625 gene and/or of a fragment, or derivative, or variant of said translation product, and/or a level of activity of said translation product, and/or of a fragment, or derivative, or variant thereof, can be detected using an immunoassay, an activity assay, and/or a binding assay. These assays can measure the amount of binding between said protein molecule and an anti-protein antibody by the use of enzymatic, chromodynamic, radioactive, magnetic, or luminescent labels which are attached to either the anti-protein antibody or a secondary antibody which binds the anti-protein antibody. In addition, other high affinity ligands may be used. Immunoassays which can be used include e.g. ELISAs, Western blots, and other techniques known to those of ordinary skill in the art (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R, *Immunodiagnostics: A Practical Approach*, Oxford University Press, Oxford; England, 1999). All these detection techniques may also be employed in the format of microarrays, protein-arrays, antibody microarrays, tissue microarrays, electronic biochip or protein-chip based technologies (see Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000).

In a preferred embodiment, the level, or the activity, or both said level and said activity of (i) a transcription product of a gene coding for Ensadin-0625, and/or of (ii) a translation product of a gene coding for Ensadin-0625, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a series of samples taken from said subject over a period of time is compared, in order to monitor the progression of said disease. In further preferred embodiments, said subject receives a treatment prior to one or more of said sample gatherings. In yet another preferred embodiment, said level and/or activity is determined before and after said treatment of said subject.

In another aspect, the invention features a kit for diagnosing or prognosticating neurodegenerative diseases, in particular AD, in a subject, or determining the

propensity or predisposition of a subject to develop a neurodegenerative disease, in particular AD, said kit comprising:

(a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of a gene coding for Ensadin-0625, and (ii) reagents that selectively detect a translation product of a gene coding for Ensadin-0625; and

(b) an instruction for diagnosing, or prognosticating a neurodegenerative disease, in particular AD, or determining the propensity or predisposition of a subject to develop such a disease by

- detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for Ensadin-0625, in a sample from said subject; and
- diagnosing or prognosticating a neurodegenerative disease, in particular AD, or determining the propensity or predisposition of said subject to develop such a disease, wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status, indicates a diagnosis or prognosis of a neurodegenerative disease, in particular AD, or an increased propensity or predisposition of developing such a disease. The kit, according to the present invention, may be particularly useful for the identification of individuals that are at risk of developing a neurodegenerative disease, in particular AD. Consequently, the kit, according to the invention, may serve as a means for targeting identified individuals for early preventive measures or therapeutic intervention prior to disease onset, before irreversible damage in the course of the disease has been inflicted. Furthermore, in preferred embodiments, the kit featured in the invention is useful for monitoring a progression of a neurodegenerative disease, in particular AD, in a subject, as well as monitoring success or failure of therapeutic treatment for such a disease of said subject.

In another aspect, the invention features a method of treating or preventing a neurodegenerative disease, in particular AD, in a subject comprising the administration to said subject in a therapeutically or prophylactically effective amount of an agent or agents which directly or indirectly affect a level, or an activity, or both said level and said activity, of (i) a gene coding for Ensadin-0625, and/or (ii)

a transcription product of a gene coding for Ensadin-0625, and/or (iii) a translation product of a gene coding for Ensadin-0625, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). Said agent may comprise a small molecule, or it may also comprise a peptide, an oligopeptide, or a polypeptide. Said peptide, oligopeptide, or polypeptide may comprise an amino acid sequence of a translation product of a gene coding for Ensadin-0625 protein, or a fragment, or derivative, or a variant thereof. An agent for treating or preventing a neurodegenerative disease, in particular AD, according to the instant invention, may also consist of a nucleotide, an oligonucleotide, or a polynucleotide. Said oligonucleotide or polynucleotide may comprise a nucleotide sequence of a gene coding for Ensadin-0625 protein, either in sense orientation or in antisense orientation.

In preferred embodiments, the method comprises the application of per se known methods of gene therapy and/or antisense nucleic acid technology to administer said agent or agents. In general, gene therapy includes several approaches: molecular replacement of a mutated gene, addition of a new gene resulting in the synthesis of a therapeutic protein, and modulation of endogenous cellular gene expression by recombinant expression methods or by drugs. Gene-transfer techniques are described in detail (see e.g. Behr, *Acc Chem Res* 1993, 26: 274-278 and Mulligan, *Science* 1993, 260: 926-931) and include direct gene-transfer techniques such as mechanical microinjection of DNA into a cell as well as indirect techniques employing biological vectors (like recombinant viruses, especially retroviruses) or model liposomes, or techniques based on transfection with DNA coprecipitation with polycations, cell membrane pertubation by chemical (solvents, detergents, polymers, enzymes) or physical means (mechanic, osmotic, thermic, electric shocks). The postnatal gene transfer into the central nervous system has been described in detail (see e.g. Wolff, *Curr Opin Neurobiol* 1993, 3: 743-748).

In particular, the invention features a method of treating or preventing a neurodegenerative disease by means of antisense nucleic acid therapy, i.e. the down-regulation of an inappropriately expressed or defective gene by the introduction of antisense nucleic acids or derivatives thereof into certain critical cells (see e.g. Gillespie, *DN&P* 1992, 5: 389-395; Agrawal and Akhtar, *Trends Biotechnol* 1995, 13: 197-199; Crooke, *Biotechnology* 1992, 10: 882-6). Apart from hybridization strategies, the application of ribozymes, i.e. RNA molecules that act as enzymes, destroying RNA that carries the message of disease has also been

described (see e.g. Barinaga, *Science* 1993, 262: 1512-1514). In preferred embodiments, the subject to be treated is a human, and therapeutic antisense nucleic acids or derivatives thereof are directed against transcripts of a gene coding for Ensadin-0625. It is preferred that cells of the central nervous system, preferably the brain, of a subject are treated in such a way. Cell penetration can be performed by known strategies such as coupling of antisense nucleic acids and derivatives thereof to carrier particles, or the above described techniques. Strategies for administering targeted therapeutic oligodeoxynucleotides are known to those of skill in the art (see e.g. Wickstrom, *Trends Biotechnol* 1992, 10: 281-287). In some cases, delivery can be performed by mere topical application. Further approaches are directed to intracellular expression of antisense RNA. In this strategy, cells are transformed *ex vivo* with a recombinant gene that directs the synthesis of an RNA that is complementary to a region of target nucleic acid. Therapeutical use of intracellularly expressed antisense RNA is procedurally similar to gene therapy. A recently developed method of regulating the intracellular expression of genes by the use of double-stranded RNA, known variously as RNA interference (RNAi), can be another effective approach for nucleic acid therapy (Hannon, *Nature* 2002, 418: 244-251).

In further preferred embodiments, the method comprises grafting donor cells into the central nervous system, preferably the brain, of said subject, or donor cells preferably treated so as to minimize or reduce graft rejection, wherein said donor cells are genetically modified by insertion of at least one transgene encoding said agent or agents. Said transgene might be carried by a viral vector, in particular a retroviral vector. The transgene can be inserted into the donor cells by a nonviral physical transfection of DNA encoding a transgene, in particular by microinjection. Insertion of the transgene can also be performed by electroporation, chemically mediated transfection, in particular calcium phosphate transfection or liposomal mediated transfection (see Mc Celland and Pardee, *Expression Genetics: Accelerated and High-Throughput Methods*, Eaton Publishing, Natick, MA, 1999).

In preferred embodiments, said agent for treating and preventing a neurodegenerative disease, in particular AD, is a therapeutic protein which can be administered to said subject, preferably a human, by a process comprising introducing subject cells into said subject, said subject cells having been treated *in vitro* to insert a DNA segment encoding said therapeutic protein, said subject cells

expressing *in vivo* in said subject a therapeutically effective amount of said therapeutic protein. Said DNA segment can be inserted into said cells *in vitro* by a viral vector, in particular a retroviral vector.

Methods of treatment, according to the present invention, comprise the application of therapeutic cloning, transplantation, and stem cell therapy using embryonic stem cells or embryonic germ cells and neuronal adult stem cells, combined with any of the previously described cell- and gene therapeutic methods. Stem cells may be totipotent or pluripotent. They may also be organ-specific. Strategies for repairing diseased and/or damaged brain cells or tissue comprise (i) taking donor cells from an adult tissue. Nuclei of those cells are transplanted into unfertilized egg cells from which the genetic material has been removed. Embryonic stem cells are isolated from the blastocyst stage of the cells which underwent somatic cell nuclear transfer. Use of differentiation factors then leads to a directed development of the stem cells to specialized cell types, preferably neuronal cells (Lanza et al., *Nature Medicine* 1999, 9: 975-977), or (ii) purifying adult stem cells, isolated from the central nervous system, or from bone marrow (mesenchymal stem cells), for in vitro expansion and subsequent grafting and transplantation, or (iii) directly inducing endogenous neural stem cells to proliferate, migrate, and differentiate into functional neurons (Peterson DA, *Curr. Opin. Pharmacol.* 2002, 2: 34-42). Adult neural stem cells are of great potential for repairing damaged or diseased brain tissues, as the germinal centers of the adult brain are free of neuronal damage or dysfunction (Colman A, *Drug Discovery World* 2001, 7: 66-71).

In preferred embodiments, the subject for treatment or prevention, according to the present invention, can be a human, an experimental animal, e.g. a mammal, a mouse, a rat, a fish, an insect, or a worm; a domestic animal, or a non-human primate. The experimental animal can be an animal model for a neurodegenerative disorder, e.g. a transgenic mouse and/or a knock-out mouse with an AD-type neuropathology.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for Ensadin-0625, and/or (ii) a transcription product of a gene coding for Ensadin-0625 and/or (iii) a translation product of a

gene coding for Ensadin-0625, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

In an additional aspect, the invention features a pharmaceutical composition comprising said modulator and preferably a pharmaceutical carrier. Said carrier refers to a diluent, adjuvant, excipient, or vehicle with which the modulator is administered.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for Ensadin-0625, and/or (ii) a transcription product of a gene coding for Ensadin-0625, and/or (iii) a translation product of a gene coding for Ensadin-0625, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for use in a pharmaceutical composition.

In another aspect, the invention provides for the use of a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for Ensadin-0625, and/or (ii) a transcription product of a gene coding for Ensadin-0625 and/or (iii) a translation product of a gene coding for Ensadin-0625, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular AD.

In one aspect, the present invention also provides a kit comprising one or more containers filled with a therapeutically or prophylactically effective amount of said pharmaceutical composition.

In a further aspect, the invention features a recombinant, non-human animal comprising a non-native gene sequence coding for Ensadin-0625, or a fragment, or a derivative, or variant thereof. The generation of said recombinant, non-human animal comprises (i) providing a gene targeting construct containing said gene sequence and a selectable marker sequence, and (ii) introducing said targeting construct into a stem cell of a non-human animal, and (iii) introducing said non-human animal stem cell into a non-human embryo, and (iv) transplanting said embryo into a pseudopregnant non-human animal, and (v) allowing said embryo to develop to term, and (vi) identifying a genetically altered non-human animal whose

genome comprises a modification of said gene sequence in both alleles, and (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said gene is mis-expressed, or under-expressed, or over-expressed, and wherein said disruption or alteration results in said non-human animal exhibiting a predisposition to developing symptoms of neuropathology similar to a neurodegenerative disease, in particular AD. Strategies and techniques for the generation and construction of such an animal are known to those of ordinary skill in the art (see e.g. Capecchi, *Science* 1989, 244: 1288-1292 and Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1994 and Jackson and Abbott, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press, Oxford, England, 1999). It is preferred to make use of such a recombinant non-human animal as an animal model for investigating neurodegenerative diseases, in particular Alzheimer's disease. Such an animal may be useful for screening, testing and validating compounds, agents and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

In another aspect, the invention features an assay for screening for a modulator of neurodegenerative diseases, in particular AD, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for Ensadin-0625, and/or (ii) a transcription product of a gene coding for Ensadin-0625, and/or (iii) a translation product of a gene coding for Ensadin-0625, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). This screening method comprises (a) contacting a cell with a test compound, and (b) measuring the activity, or the level, or both the activity and the level of one or more substances recited in (i) to (iv), and (c) measuring the activity, or the level, or both the activity and the level of said substances in a control cell not contacted with said test compound, and (d) comparing the levels of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of said substances in the contacted cells indicates that the test compound is a modulator of said diseases and disorders.

In one further aspect, the invention features a screening assay for a modulator of neurodegenerative diseases, in particular AD, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for

Ensadin-0625, and/or (ii) a transcription product of a gene coding for Ensadin-0625, and/or (iii) a translation product of a gene coding for Ensadin-0625, and/or (iv) a fragment, or derivative, or variant of (i) to (iii), comprising (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders, and (b) measuring the activity and/or level of one or more substances recited in (i) to (iv), and (c) measuring the activity and/or level of said substances in a matched control animal which is equally predisposed to developing or has already developed said symptoms and to which animal no such test compound has been administered, and (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases and disorders.

In a preferred embodiment, said test animal and/or said control animal is a recombinant, non-human animal which expresses a gene coding for Ensadin-0625, or a fragment thereof, or a derivative, or a variant thereof, under the control of a transcriptional regulatory element which is not the native Ensadin-0625 gene transcriptional control regulatory element.

In another embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases by a method of the aforementioned screening assays and (ii) admixing the modulator with a pharmaceutical carrier. However, said modulator may also be identifiable by other types of screening assays.

In another aspect, the present invention provides for an assay for testing a compound, preferably for screening a plurality of compounds, for inhibition of binding between a ligand and a translation product of a gene coding for Ensadin-0625, or a fragment, or derivative, or variant thereof. Said screening assay comprises the steps of (i) adding a liquid suspension of said Ensadin-0625 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a compound or a plurality of compounds to be screened for said inhibition to said plurality of containers, and (iii) adding a detectable, preferably a fluorescently labelled ligand to said containers, and (iv) incubating said Ensadin-0625 translation product, or said fragment, or derivative, or variant thereof,

and said compound or plurality of compounds, and said detectable, preferably fluorescently labelled ligand, and (v) measuring the amounts of preferably fluorescence associated with said Ensadin-0625 translation product, or with said fragment, or derivative, or variant thereof, and (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said Ensadin-0625 translation product, or said fragment, or derivative, or variant thereof. It might be preferred to reconstitute said Ensadin-0625 translation product, or fragment, or derivative, or variant thereof into artificial liposomes to generate the corresponding proteoliposomes to determine the inhibition of binding between a ligand and said Ensadin-0625 translation product. Methods of reconstitution of Ensadin-0625 translation products from detergent into liposomes have been detailed (Schwarz et al., *Biochemistry* 1999, 38: 9456-9464; Krivosheev and Usanov, *Biochemistry-Moscow* 1997, 62: 1064-1073). Instead of utilizing a fluorescently labelled ligand, it might in some aspects be preferred to use any other detectable label known to the person skilled in the art, e.g. radioactive labels, and detect it accordingly. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to inhibit the binding of a ligand to a gene product of the gene coding for Ensadin-0625, or a fragment, or derivative, or variant thereof. One example of a fluorescent binding assay, in this case based on the use of carrier particles, is disclosed and described in patent application WO 00/52451. A further example is the competitive assay method as described in patent WO 02/01226. Preferred signal detection methods for screening assays of the instant invention are described in the following patent applications: WO 96/13744, WO 98/16814, WO 98/23942, WO 99/17086, WO 99/34195, WO 00/66985, WO 01/59436, WO 01/59416.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a gene product of a gene coding for Ensadin-0625 by the aforementioned inhibitory binding assay and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another aspect, the invention features an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to a translation product of a gene coding for Ensadin-0625, or to

a fragment, or derivative, or variant thereof. Said screening assay comprises (i) adding a liquid suspension of said Ensadin-0625 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a detectable, preferably a fluorescently labelled compound or a plurality of detectable, preferably fluorescently labelled compounds to be screened for said binding to said plurality of containers, and (iii) incubating said Ensadin-0625 translation product, or said fragment, or derivative, or variant thereof, and said detectable, preferably fluorescently labelled compound or detectable, preferably fluorescently labelled compounds, and (iv) measuring the amounts of preferably the fluorescence associated with said Ensadin-0625 translation product, or with said fragment, or derivative, or variant thereof, and (v) determining the degree of binding by one or more of said compounds to said Ensadin-0625 translation product, or said fragment, or derivative, or variant thereof. In this type of assay it might be preferred to use a fluorescent label. However, any other type of detectable label might also be employed. Also in this type of assay it might be preferred to reconstitute an Ensadin-0625 translation product or a fragment, or derivative, or variant thereof into artificial liposomes as described in the present invention. Said assay methods may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to bind to an Ensadin-0625 translation product, or fragment, or derivative, or variant thereof.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a gene product of the Ensadin-0625 gene by the aforementioned binding assays and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another embodiment, the present invention provides for a medicament obtainable by any of the methods according to the herein claimed screening assays. In one further embodiment, the instant invention provides for a medicament obtained by any of the methods according to the herein claimed screening assays.

The present invention features a protein molecule shown in SEQ ID NO. 1, said protein molecule being a translation product of the gene coding for an Ensadin-0625 protein, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.

The present invention further features a protein molecule shown in SEQ ID NO. 1, said protein molecule being a translation product of the gene coding for an Ensadin-0625 protein, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

The present invention features an antibody which is specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for Ensadin-0625, or a fragment, or variant, or derivative thereof. The immunogen may comprise immunogenic or antigenic epitopes or portions of a translation product of said gene, wherein said immunogenic or antigenic portion of a translation product is a polypeptide, and wherein said polypeptide elicits an antibody response in an animal, and wherein said polypeptide is immunospecifically bound by said antibody. Methods for generating antibodies are well known in the art (see Harlow et al., *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988). The term "antibody", as employed in the present invention, encompasses all forms of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial, anti-idiotypic, humanized, or single chain antibodies, as well as fragments thereof (see Dubel and Breitling, *Recombinant Antibodies*, Wiley-Liss, New York, NY, 1999). Antibodies of the present invention are useful, for instance, in a variety of diagnostic and therapeutic methods, based on state-in-the-art techniques (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R., *Immunodiagnostics: A Practical Approach*, Oxford University Press, Oxford, England, 1999) such as enzyme-immuno assays (e.g. enzyme-linked immunosorbent assay, ELISA), radioimmuno assays, chemoluminescence-immuno assays, Western-blot, immunoprecipitation and antibody microarrays. These methods involve the detection of translation products of the Ensadin-0625 gene, or fragments, or derivatives, or variants thereof.

In a preferred embodiment of the present invention, said antibodies can be used for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell.

Preferably, the pathological state relates to a neurodegenerative disease, in particular to AD. Immunocytochemical staining of a cell can be carried out by a number of different experimental methods well known in the art. It might be preferred, however, to apply an automated method for the detection of antibody binding, wherein the determination of the degree of staining of a cell, or the determination of the cellular or subcellular staining pattern of a cell, or the topological distribution of an antigen on the cell surface or among organelles and other subcellular structures within the cell, are carried out according to the method described in US patent 6150173.

Other features and advantages of the invention will be apparent from the following description of figures and examples which are illustrative only and not intended to limit the remainder of the disclosure in any way.

Figure 1 depicts the brain regions with selective vulnerability to neuronal loss and degeneration in AD. Primarily, neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus, and the amygdala are subject to degenerative processes in AD (Terry et al., *Annals of Neurology* 1981, 10: 184-192). These brain regions are mostly involved in the processing of learning and memory functions. In contrast, neurons within the frontal cortex, the occipital cortex, and the cerebellum remain largely intact and preserved from neurodegenerative processes in AD. Brain tissues from the frontal cortex (F), the temporal cortex (T), and the hippocampus (H) of AD patients and healthy, age-matched control individuals were used for the herein disclosed examples. For illustrative purposes, the image of a normal healthy brain was taken from a publication by Strange (*Brain Biochemistry and Brain Disorders*, Oxford University Press, Oxford, 1992, p.4).

Figure 2 discloses the initial identification of the differential expression of the gene coding for Ensadin-0625 in a fluorescence differential display screen. The figure shows a clipping of a large preparative fluorescent differential display gel. PCR products from the frontal cortex (F) and the temporal cortex (T) of two healthy control subjects and six AD patients were loaded in duplicate onto a denaturing polyacrylamide gel (from left to right). PCR products were obtained by amplification of the individual cDNAs with the corresponding one-base-anchor oligonucleotide and the specific Cy3 labelled random primers. The arrow indicates the migration position where significant differences in intensity of the signals for a transcription product of

the gene coding for Ensadin-0625 derived from frontal cortex as compared to the signals derived from the temporal cortex of AD patients exist. The differential expression reflects a down-regulation of Ensadin-0625 gene transcription in the temporal cortex compared to the frontal cortex of AD patients. Comparing the signals derived from temporal cortex and frontal cortex of healthy non-AD control subjects with each other, no difference in signal intensity, i.e. no altered expression level can be detected.

Figures 3 and 4 illustrate the verification of the differential expression of the human Ensadin-0625 gene in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (Figure 3a) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (Figure 4a) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (Figure 3b for frontal cortex and temporal cortex, Figure 4b for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for cyclophilin B, the ribosomal protein S9, the transferrin receptor, GAPDH, and beta-actin. The figures depict the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of Ensadin-0625 cDNAs from both, the frontal and temporal cortices of a normal control individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (Figures 3b and 4b, arrowhead), whereas in Alzheimer's disease (Figures 3a and 4a, arrowhead) there is a significant separation of the corresponding curves, indicating a differential expression of the gene coding for Ensadin-0625 in the respective analyzed brain regions.

Figure 5 discloses SEQ ID NO. 1, the amino acid sequence of the Ensadin-0625 protein. The full length human Ensadin-0625 protein comprises 307 amino acids.

Figure 6 shows SEQ ID NO. 2, the nucleotide sequence of the human Ensadin-0625 cDNA, comprising 5691 nucleotides.

Figure 7 depicts SEQ ID NO. 3, the nucleotide sequence of the 377 bp Ensadin-0625 cDNA fragment, identified and obtained by differential display (sequence in 5' to 3' direction).

Figure 8 outlines the sequence alignment of SEQ ID NO. 3 to the nucleotide sequence of the human Ensadin-0625 cDNA (GenBank accession number: AF288395).

Figure 9 charts the schematic alignment of SEQ ID NO. 3 with Ensadin-0625 cDNA. The open rectangle represents the Ensadin-0625 open reading frame, thin bars represent the 5' and 3' untranslated regions (UTRs).

Table 1 lists Ensadin-0625 gene expression levels in the temporal cortex relative to the frontal cortex in seven AD patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (0.34 to 1.03 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.79 to 2.30 fold). The scatter plot diagram visualizes individual values of the temporal to frontal cortex regulation ratios in control samples (dots) and in AD patient samples (triangles), respectively. The values shown are calculated according to the formula described herein (see below).

Table 2 lists the gene expression levels in the hippocampus relative to the frontal cortex for the Ensadin-0625 gene in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (0.15 to 0.78 fold) and three healthy, age-matched control individuals, herein identified by internal reference numbers C004, C005, C008 (0.68 to 0.96 fold). The scatter plot diagram visualizes individual values of the hippocampus to frontal cortex regulation ratios in control samples (dots) and in AD patient samples (triangles). The values shown are calculated according to the formula described herein (see below).

EXAMPLE I:

(i) Brain tissue dissection from patients with AD:

Brain tissues from AD patients and age-matched control subjects were collected on average within 5 hours post-mortem and immediately frozen on dry ice. Sample

sections from each tissue were fixed in paraformaldehyde for histopathological confirmation of the diagnosis. Brain areas for differential expression analysis were identified (see Figure 1) and stored at -80°C until RNA extractions were performed.

(ii) Isolation of total mRNA:

Total RNA was extracted from post-mortem brain tissue by using the RNeasy kit (Qiagen) according to the manufacturer's protocol. The accurate RNA concentration and the RNA quality were determined with the DNA LabChip system using the Agilent 2100 Bioanalyzer (Agilent Technologies). For additional quality testing of the prepared RNA, i.e. exclusion of partial degradation and testing for DNA contamination, specifically designed intronic GAPDH oligonucleotides and genomic DNA as reference control were used to generate a melting curve with the LightCycler technology as described in the manufacturer's protocol (Roche).

(iii) cDNA synthesis and identification of differentially expressed genes by fluorescence differential display (FDD):

In order to identify changes in gene expression in different tissues we employed a modified and improved differential display (DD) screening method. The original DD screening method is known to those skilled in the art (Liang and Pardee, *Science* 1995, 267:1186-7). This technique compares two populations of RNA and provides clones of genes that are expressed in one population but not in the other. Several samples can be analyzed simultaneously and both up- and down-regulated genes can be identified in the same experiment. By adjusting and refining several steps in the DD method as well as modifying technical parameters, e.g. increasing redundancy, evaluating optimized reagents and conditions for reverse transcription of total RNA, optimizing polymerase chain reactions (PCR) and separation of the products thereof, a technique was developed which allows for highly reproducible and sensitive results. The applied and improved DD technique was described in detail by von der Kammer et al. (*Nucleic Acids Research* 1999, 27: 2211-2218). A set of 64 specifically designed random primers were developed (standard set) to achieve a statistically comprehensive analysis of all possible RNA species. Further, the method was modified to generate a preparative DD slab-gel technique, based on the use of fluorescently labelled primers. In the present invention, RNA populations from carefully selected post-mortem brain tissues (frontal and temporal cortex) of Alzheimer's disease patients and age-matched control subjects were compared.

As starting material for the DD analysis we used total RNA, extracted as described above (ii). Equal amounts of 0.05 µg RNA each were transcribed into cDNA in 20 µl reactions containing 0.5 mM each dNTP, 1 µl Sensiscript Reverse Transcriptase and 1x RT buffer (Qiagen), 10 U RNase inhibitor (Qiagen) and 1 µM of either one-base-anchor oligonucleotides $HT_{11}A$, $HT_{11}G$ or $HT_{11}C$ (Liang et al., *Nucleic Acids Research* 1994, 22: 5763-5764; Zhao et al., *Biotechniques* 1995, 18:842-850). Reverse transcription was performed for 60 min at 37 °C with a final denaturation step at 93 °C for 5 min. 2 µl of the obtained cDNA each was subjected to a polymerase chain reaction (PCR) employing the corresponding one-base-anchor oligonucleotide (1 µM) along with either one of the Cy3 labelled random DD primers (1 µM), 1x GeneAmp PCR buffer (Applied Biosystems), 1.5 mM $MgCl_2$ (Applied Biosystems), 2 µM dNTP-Mix (dATP, dGTP, dCTP, dTTP Amersham Pharmacia Biotech), 5 % DMSO (Sigma), 1 U AmpliTaq DNA Polymerase (Applied Biosystems) in a 20 µl final volume. PCR conditions were set as follows: one round at 94 °C for 30 sec for denaturing, cooling 1 °C/sec down to 40 °C, 40 °C for 4 min for low-stringency annealing of primer, heating 1 °C/sec up to 72 °C, 72 °C for 1 min for extension. This round was followed by 39 high-stringency cycles: 94 °C for 30 sec, cooling 1 °C/sec down to 60 °C, 60 °C for 2 min, heating 1 °C/sec up to 72 °C, 72 °C for 1 min. One final step at 72 °C for 5 min was added to the last cycle (PCR cycler: Multi Cycler PTC 200, MJ Research). 8 µl DNA loading buffer were added to the 20 µl PCR product preparation, denatured for 5 min and kept on ice until loading onto a gel. 3.5 µl each were separated on 0.4 mm thick, 6 %-polyacrylamide (Long Ranger)/ 7 M urea sequencing gels in a slab-gel system (Hitachi Genetic Systems) at 2000 V, 60W, 30 mA, for 1 h 40 min. Following completion of the electrophoresis, gels were scanned with a FMBIO II fluorescence-scanner (Hitachi Genetic Systems), using the appropriate FMBIO II Analysis 8.0 software. A full-scale picture was printed, differentially expressed bands marked, excised from the gel, transferred into 1.5 ml containers, overlayed with 200 µl sterile water and kept at -20°C until extraction.

Elution and reamplification of differential display products: The differential bands were extracted from the gel by boiling in 200 µl H_2O for 10 min, cooling down on ice and precipitation from the supernatant fluids by using ethanol (Merck) and glycogen/sodium acetate (Merck) at -20 °C over night, and subsequent centrifugation at 13.000 rpm for 25 min at 4 °C. Pellets were washed twice in ice-cold ethanol (80%), resuspended in 10 mM Tris pH 8.3 (Merck) and dialysed against 10 % glycerol (Merck) for 1 h at room temperature on a 0.025 µm VSWP membrane

(Millipore). The obtained preparations were used as templates for reamplification by 15 high-stringency cycles in 25-µl PCR mixtures containing the corresponding primer pairs as used for the differential display PCR (see above) under identical conditions, with the exception of the initial round at 94 °C for 5 min, followed by 15 cycles of: 94 °C for 45 sec, 60 °C for 45 sec, ramp 1°C/sec to 70 °C for 45 sec, and one final step at 72 °C for 5 min.

Cloning and sequencing of differential display products: Re-amplified cDNAs were analyzed with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies) and were ligated into the pCR-Blunt II-TOPO vector and transformed into E.coli Top10F' cells (Zero Blunt TOPO PCR Cloning Kit, Invitrogen) according to the manufacturer's instructions. Cloned cDNA fragments were sequenced by commercially available sequencing facilities. The results of one such fluorescence differential display experiment for the human Ensadin-0625 gene are shown in Figure 2.

(iv) Confirmation of differential expression by quantitative RT-PCR:

Positive corroboration of differential expression of the gene coding for Ensadin-0625 was performed using the LightCycler technology (Roche). This technique features rapid thermal cyling for the polymerase chain reaction as well as real-time measurement of fluorescent signals during amplification and therefore allows for highly accurate quantification of RT-PCR products by using a kinetic, rather than an endpoint readout. The ratios of Ensadin-0625 cDNA from the temporal cortex and frontal cortex, and from the hippocampus and frontal cortex, respectively, were determined (relative quantification).

First, a standard curve was generated to determine the efficiency of the PCR with specific primers for the gene coding for Ensadin-0625: 5'-AACGGCTCTTTCCCTCAACC-3' and 5'-CCTCAAGACCATGTGGATCCA-3'. PCR amplification (95 °C and 1 sec, 56 °C and 5 sec, and 72 °C and 5 sec) was performed in a volume of 20 µl containing LightCycler-FastStart DNA Master SYBR Green I mix (contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix with dUTP instead of dTTP, SYBR Green I dye, and 1 mM $MgCl_2$; Roche), 0.5 µM primers, 2 µl of a cDNA dilution series (final concentration of 40, 20, 10, 5, 1 and 0.5 ng human total brain cDNA; Clontech) and, depending on the primers used, additional 3 mM $MgCl_2$. Melting curve analysis revealed a single peak at approximately 82.5°C with no visible primer dimers. Quality and size of the PCR

product were determined with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies). A single peak at the expected size of 71 bp for the Ensadin-0625 gene was observed in the electropherogram of the sample.

In an analogous manner, the PCR protocol was applied to determine the PCR efficiency of a set of reference genes which were selected as a reference standard for quantification. In the present invention, the mean value of five such reference genes was determined: (1) cyclophilin B, using the specific primers 5'-ACTGAAGCACTACGGGCCTG-3' and 5'-AGCCGTTGGTGTCTT TGCC-3' except for $MgCl_2$ (an additional 1 mM was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 87 °C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band of the expected size (62 bp). (2) Ribosomal protein S9 (RPS9), using the specific primers 5'-GGTCAAATTTACCCTGGCCA-3' and 5'- TCTCATCAAGCGTCAGCAGTTC-3' (exception: additional 1 mM $MgCl_2$ was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 85°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (62 bp). (3) beta-actin, using the specific primers 5'-TGGAACGGTGAAGGTGACA-3' and 5'-GGCAAGGGACTTCCTGTAA-3'. Melting curve analysis revealed a single peak at approximately 87°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (142 bp). (4) GAPDH, using the specific primers 5'-CGTCATGGGTGTGAACCATG-3' and 5'-GCTAAGCAGTTGGTGGTGCAG-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (81 bp). (5) Transferrin receptor TRR, using the specific primers 5'-GTCGCTGGTCAGTTCGTGATT-3' and 5'-AGCAGTTGGCTGTTGTACCTCTC-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (80 bp).

For calculation of the values, first the logarithm of the cDNA concentration was plotted against the threshold cycle number C_t for the gene coding for Ensadin-0625 and the five reference standard genes. The slopes and the intercepts of the standard curves (i.e. linear regressions) were calculated for all genes. In a second step, cDNAs from temporal cortex and frontal cortex, and from hippocampus and

frontal cortex, respectively, were analyzed in parallel and normalized to cyclophilin B. The C_t values were measured and converted to ng total brain cDNA using the corresponding standard curves:

$$10 \wedge ((C_t \text{ value} - \text{intercept}) / \text{slope}) \quad [\text{ng total brain cDNA}]$$

The values for temporal and frontal cortex Ensadin-0625 cDNAs, and the values for hippocampus and frontal cortex Ensadin-0625 cDNAs, respectively, were normalized to cyclophilin B and the ratios were calculated according to formulas:

$$\text{Ratio} = \frac{\text{Ensadin-0625 temporal [ng] / cyclophilin B temporal [ng]}}{\text{Ensadin-0625 frontal [ng] / cyclophilin B frontal [ng]}}$$

$$\text{Ratio} = \frac{\text{Ensadin-0625 hippocampus [ng] / cyclophilin B hippocampus [ng]}}{\text{Ensadin-0625 frontal [ng] / cyclophilin B frontal [ng]}}$$

In a third step, the set of reference standard genes was analyzed in parallel to determine the mean average value of the temporal to frontal ratios, and of the hippocampal to frontal ratios, respectively, of expression levels of the reference standard genes for each individual brain sample. As cyclophilin B was analyzed in step 2 and step 3, and the ratio from one gene to another gene remained constant in different runs, it was possible to normalize the values for Ensadin-0625 to the mean average value of the set of reference standard genes instead of normalizing to one single gene alone. The calculation was performed by dividing the respective ratio shown above by the deviation of cyclophilin B from the mean value of all housekeeping genes. The results of such quantitative RT-PCR analysis for the Ensadin-0625 gene are shown in Figures 3 and 4.

CLAIMS

1. A method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease, comprising determining a level and/or an activity of

(i) a transcription product of a gene coding for Ensadin-0625, and/or

(ii) a translation product of a gene coding for Ensadin-0625, and/or

(iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

2. The method according to claim 1 wherein said neurodegenerative disease is Alzheimer's disease.

3. A kit for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop such a disease, said kit comprising:

(a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of a gene coding for Ensadin-0625 and (ii) reagents that selectively detect a translation product of a gene coding for Ensadin-0625; and

(b) an instruction for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by (i) detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for Ensadin-0625, in a sample from said subject; and (ii) diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of said subject to develop such a disease, wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said

transcription product and/or said translation product similar or equal to a reference value representing a known disease status indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease.

4. A modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of

(i) a gene coding for Ensadin-0625, and/or

(ii) a transcription product of a gene coding for Ensadin-0625, and/or

(iii) a translation product of a gene coding for Ensadin-0625, and/or

(iv) a fragment, or derivative, or variant of (i) to (iii).

5. A recombinant, non-human animal comprising a non-native gene sequence coding for Ensadin-0625 or a fragment, or a derivative, or a variant thereof, said animal being obtainable by:

(i) providing a gene targeting construct comprising said gene sequence and a selectable marker sequence, and

(ii) introducing said targeting construct into a stem cell of a non-human animal, and

(iii) introducing said non-human animal stem cell into a non-human embryo, and

(iv) transplanting said embryo into a pseudopregnant non-human animal, and

(v) allowing said embryo to develop to term, and

(vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and

(vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said disruption results in said non-human animal exhibiting a predisposition to developing symptoms of a neurodegenerative disease or related diseases or disorders.

6. An assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

(i) a gene coding for Ensadin-0625, and/or

(ii) a transcription product of a gene coding for Ensadin-0625, and/or

(iii) a translation product of a gene coding for Ensadin-0625, and/or

(iv) a fragment, or derivative, or variant of (i) to (iii),

said method comprising:

(a) contacting a cell with a test compound;

(b) measuring the activity and/or level of one or more substances recited in (i) to (iv);

(c) measuring the activity and/or level of one or more substances recited in (i) to (iv) in a control cell not contacted with said test compound; and

(d) comparing the levels and/or activities of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of substances in the contacted cells indicates that the test compound is a modulator of said diseases or disorders.

7. A method of screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

(i) a gene coding for Ensadin-0625, and/or

(ii) a transcription product of a gene coding for Ensadin-0625, and/or

(iii) a translation product of a gene coding for Ensadin-0625, and/or

(v) a fragment, or derivative, or variant of (i) to (iii),

said method comprising:

(a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect of the substances recited in (i) to (iv);

(b) measuring the activity and/or level of one or more substances recited in (i) to (iv);

(c) measuring the activity and/or level of one or more substances recited in (i) or (iv) in a matched control animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders in respect to the substances recited in (i) to (iv) and to which animal no such test compound has been administered;

(d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases or disorders.

8. The method according to claim 7 wherein said test animal and/or said control animal is a recombinant animal which expresses Ensadin-0625, or a fragment, or a derivative, or a variant thereof, under the control of a transcriptional control element which is not the native Ensadin-0625 gene transcriptional control element.

9. An assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to an Ensadin-0625 translation product, or to a fragment, or derivative, or variant thereof, said assay comprising the steps of:

(i) adding a liquid suspension of said Ensadin-0625 translation product, or a fragment, or derivative, or variant thereof, to a plurality of containers;

(ii) adding a detectable, in particular a fluorescently labelled compound or a plurality of detectable, in particular fluorescently labelled compounds to be screened for said binding to said plurality of containers;

(iii) incubating said Ensadin-0625 translation product, or said fragment, or derivative, or variant thereof, and said detectable, in particular fluorescently labelled compound or fluorescently labelled compounds;

(iv) measuring amounts of preferably the fluorescence associated with said Ensadin-0625 translation product, or with said fragment, or derivative, or variant thereof; and

(v) determining the degree of binding by one or more of said compounds to said Ensadin-0625 translation product, or said fragment, or derivative, or variant thereof.

10. A protein molecule, said protein molecule being a translation product of the gene coding for Ensadin-0625, SEQ ID NO. 1, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.

11. A protein molecule, said protein molecule being a translation product of the gene coding for Ensadin-0625, SEQ ID NO.1, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

12. Use of an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for Ensadin-0625, SEQ ID NO. 1, or a fragment, or derivative, or variant thereof, for detecting a pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell.



Fig. 1: Identification of Genes Involved in Alzheimer's Disease Pathology



Fig. 2: Identification of differentially expressed genes in a fluorescence differential display screen



Fig. 3: Verification of differential expression of Ensadin-0625 by quantitative RT-PCR



Fig. 4: Verification of differential expression of Ensadin-0625 by quantitative RT-PCR

Fig. 5: SEQ ID NO. 1:
amino acid sequence of human Ensadin-0625 protein

Length: 307 aa

```
  1  MTETTKTHVI LLACGSFNPI TKGHIQMFER ARDYLHKTGR FIVIGGIVSP
 51  VHDSYGKQGL VSSRHRLIMC QLAVQNSDWI RVDPWECYQD TWQTTCSVLE
101  HHRDLMKRVT GCILSNVNTP SMTPVIGQPQ NETPQPIYQN SNVATKPTAA
151  KILGKVGESL SRICCVRPPV ERFTFVDENA NLGTVMRYEE IELRILLLCG
201  SDLLESFCIP GLWNEADMEV IVGDFGIVVV PRDAADTDRI MNHSSILRKY
251  KNNIMVVKDD INHPMSVVSS TKSRLALQHG DGHVVDYLSQ PVIDYILKSQ
301  LYINASG
```

Fig. 6: SEQ ID NO. 2: nucleotide sequence of human Ensadin-0625 cDNA

Length: 5691 bp

```
   1  ATATAAACTC TAAGGAAGAC AGTGATGGAG TGAAGTGGGC TGGGGGCGAT
  51  AGAGAGGATG GGGTGGGGCA CCAGGCGAGA GATGCGAAGG AAGCCAGAAC
 101  GAAAAGAGAG CGACCGAGGA GAGAAGAGAG CAGAGCAATA CAAAAGCAGC
 151  CTCGGATCTA GCCGGAGCTG CAAGCGTTAA GGGGAGGCGG AGAGTGACGC
 201  GGTTTGCGTC TGGAGCGGCT CCTTGGAGTC CACAGCATCC ACCGCCGGAG
 251  CCTCGCCTTC CTTTCTCCCT CTGCAGACAC AACGAGACAC AAAAAGAGAG
 301  GCAACCCCTA GACCACCGCG AAGGACCCAT CTGCACCATG ACCGAGACCA
 351  CCAAGACCCA CGTTATCTTG CTCGCCTGCG GCAGCTTCAA TCCCATCACC
 401  AAAGGGCACA TTCAGATGTT TGAAAGAGCC AGGGATTATC TGCACAAAAC
 451  TGGAAGGTTT ATTGTGATTG GCGGGATTGT CTCCCCTGTC CACGACTCCT
 501  ATGGAAAACA GGGCCTCGTG TCAAGCCGGC ACCGTCTCAT CATGTGTCAG
 551  CTGGCCGTCC AGAATTCTGA TTGGATCAGG GTGGACCCTT GGGAGTGCTA
 601  CCAGGACACC TGGCAGACGA CCTGCAGCGT GTTGGAACAC CACCGGGACC
 651  TCATGAAGAG GGTGACTGGC TGCATCCTCT CCAATGTCAA CACACCTTCC
 701  ATGACACCTG TGATCGGACA GCCACAAAAC GAGACCCCCC AGCCCATTTA
 751  CCAGAACAGC AACGTGGCCA CCAAGCCCAC TGCAGCCAAG ATCTTGGGGA
 801  AGGTGGGAGA AAGCCTCAGC CGGATCTGCT GTGTCCGCCC GCCGGTGGAG
 851  CGTTTCACCT TTGTAGATGA GAATGCCAAT CTGGGCACGG TGATGCGGTA
 901  TGAAGAGATT GAGCTACGGA TCCTGCTGCT GTGTGGTAGT GACCTGCTGG
 951  AGTCCTTCTG CATCCCAGGG CTCTGGAACG AGGCAGATAT GGAGGTGATT
1001  GTTGGTGACT TTGGGATTGT GGTGGTGCCC CGGGATGCAG CCGACACAGA
1051  CCGAATCATG AATCACTCCT CAATACTCCG CAAATACAAA AACAACATCA
1101  TGGTGGTGAA GGATGACATC AACCATCCCA TGTCTGTTGT CAGCTCAACC
1151  AAGAGCAGGC TGGCCCTGCA GCATGGGGAC GGCCATGTTG TGGATTACCT
1201  GTCCCAGCCG GTCATCGACT ACATCCTCAA AAGCCAGCTG TACATCAATG
1251  CCTCCGGCTA GCAGCCCCTC GTCCTCCGGC AACACAATGG CCCCTCCATC
1301  TTTGTCAGCC CCCTGTTTCT CTCCTGCCTC TCTGTTTCTC CATCTCCTCG
1351  TCTTGACTGT TTTCCCTACT TGCTGACTTA ACCCCCCATA GTGTGGGGGA
1401  CCTGCAGAGA ACCATGGCAT TCCCTATTCC ACAGTCATCT TTGGACAGAC
1451  TTTCCTCTAG TCTCCGGGTT GGGGGTGGGT GAGGGAATGG GGTGGGAGTC
1501  GGGGGAAGTG CAGTCCTTGG AGATGTACTG GTGTCCGTCT CCCAGCATGC
1551  TCTAGAGAGG CGGCTCTGGT GCCCATCCTC CCAGCACGCT CTGGGGAGGC
1601  GGCTCTGGTG CCCATCCTCC CAGCATGCTC TAGAGAGGCG GCTCTGGTGC
1651  CCCTCCTCCC AGCATGCTCT GGGGAGGCGG CTCTGGCTCT TGCCTTCCCA
1701  GCATGCCCTT TACTACAAAG GGCTATTTTT CTTTTCTTTC TTTTGTTTAT
1751  TTATTTTTCT TTGTTCACTC CCTGTAGAAC TTGGATGAAA TCAGTGTCCA
1801  TGGTTCTTTA TGTTTGTAGT CTTGATGTGC TCCTGTGGTA TTACTTCCCC
1851  TCTGATAGGA CATTGTAGCC AGCCTCAGCA CTCAGTGAGT TCATCAGGGC
1901  CACACCCAGT AGAGAAGGCC AAGCAACCTC CACTTCTTCA GCACCACACA
1951  CACGCACACA CACACACACG CACACATGCG TGTGCACCCG CGCACGCACA
2001  TACACACACA CATATAGCAG TAGCAGCAGC AGCAGCAGCA GCAGCAACCT
2051  TTGATCAGGA GTGAGATTTT CGGGTTCTGA AACCTGGGAC ACGAGTCTGT
2101  GAATAGTCGG TTTTCTCAGA ATAATTTGAA TCTGTTTTCT TAGTTTCAAA
2151  TGACCATTTC CCTGATGCTC TGAGCTTATG ATCACACAGA GCCAGTCCAT
2201  CCTCATTTCC TGGTGGCATC TGTTCATTTA CCTTTGTGGA CTGTAGCTGA
2251  TGGCACAGTG CGGGTTCCCT ACCAGCCAGG GGTTTCCAAG GGACCTTTGG
2301  AGGCCATGCT TAGACACATT CCTGTACCTG AGAACAACCA CATAGGCAGG
```

```
2351  ACCAGATCCA CATCGTGCAG TCGTGTCATA AAAAAACAAA ACAAAACAAA
2401  AAAACACTAG GAGTCCACTC AACCCTGGAG GTCTTTGCTA ATTGGAATTA
2451  TGTATTGTCT GTTGGGCTGG GAAATGTCTC TTTCATATTG TAAGTCCAGG
2501  ATGAACTAGG AGAAAGCAAT TTGTTGCCCT GATGATAACT GATGATTTTC
2551  ACCCTCTCTA GCTGAGGTAA CTCAGACAGT GCATGAGGTC AGTTTCTTCT
2601  TGAGAAGCAG TGCCTTGGTC TTGTTTCTGT GGTTGGTTCT AGCCCCTGCA
2651  GAGCCTGGGA GCTGCAGGAA CTGTCTGAGA AAATCTCCCT AATAGGGGAG
2701  TGGGTTCCCA GAAGGGAGAT CTGGGAGGGG TCAGGAGCCA CTAAGTTGCT
2751  TCACTCCTTT TTTCTCTAAT TTTCTACCTT CCTCTCTGTT CCTGCAGACA
2801  GTTTTGCCAG CTTTGCTTCT GGTTACTAGG GTCTCATGCG TGTCCTGCTT
2851  GGAGAGCCAT AAGGAAATTG CTGTCTTGTG CTTTGTGTCT CTCATCCAGT
2901  CTCTGGCTCT TGGGATTCTG GTCTTTGAGA AATAGTCCCT GAGTATTAGG
2951  ATACTTTTAT CAAAATCTAG TACCAGCTAC GGCCAGAAAG GGCCAGGTGG
3001  GACCTGAAAG CAAAGACAAT GTTCTTTACC ACACGTTTCA CATCTGCAAC
3051  ATCCTTCAAT TGCGGGAAAA GGAACTTGAT TTAACAGAAG AACATGGTAG
3101  AGCAGCATCC AGAAAGTCTG TTATTCCTCT TGGATTTTTT GAAATAATCT
3151  TCAGAGGAAG GAAGGAAAAT CCTATTTTGG GGTATCAGTG TTTGACTAGG
3201  GATCATGAAA TAATAAACTG AAAAAAACTT TAGAGTTCAG TTGATCCAAC
3251  ACTTTCCTTT AAAAGTTGAG GGAGCAGAGG CCCATGGGAT TAAATGGCTG
3301  GTCCAGGTCA GCCAGCAGGT GTAGGGCCTG ACAAGAACAT ATTGTTTCCC
3351  TGACCCCTAG GCCGTCACAC CACACCCTCC ATTTCCTCAT GTTGCTGACC
3401  AGGTGCCCAT ATGATTTCTA CACTTCCCAA GCCTTACCCT GGCATCTTTC
3451  TTTTAAATTA TATCTGTCCC AGGTGCTCTC CACACATAGG ATGGTAATGC
3501  CAGTCCCAGG GGAGGGTGTG ATAGTAAGGA AGGCCACTGT TAGGTTTCCT
3551  TTAGAAATAA AGAGATCTCA GCAGCTTGGA AGAAATCCCA GAAGCGGAAC
3601  TCCATCAATC CAAGAAAGAG TTGCTTTGTG GAAGGTGAAG GAAGACCCAC
3651  AGAGTGCTCA GGATGATGCT ATTGCTGGAG AGCGAAAGAT GGAACAGCCT
3701  TGTCCAGGCA GAACAGTCAT AAGCCAGGAA ATGAAACAAA GGAAAACAGG
3751  TGCCTGAATT TCCTGGGGAA ACATGGCTTG TTTAAGGACT TGGAGTTATG
3801  GATGGAATTT ATGGGACCCA CGTGAGCAGA CCTGAGGAAG GCTCGATTTC
3851  TTTTGTTTCT TGGTCCACTC TGTCACTCTG CTCTGGTCAA GCCCCATTTG
3901  GTCTACAGCC CATGAGAAGG AATGAGGCTG GTTCTGCACT CTCAGCATGC
3951  AGTCCGAAAG CATGTGGGAG TGGGGAGGGA AAGTGAGATG AATTAAGACA
4001  AAGAACAGGT GCCATAGAAG TAGATTTCTA GGAATGAAGT GGGGCAGATC
4051  TTATCTTTGT GGATTACAGG CACTGTACTA AAAACAGGTT TCCTATTTAA
4101  TATAAAAAGA AAGTGAATCT TCTTTTGGAT AGAATCATCC ATTCCCATCG
4151  CCGCACCCCC TACCCCCCAA ACACACACAC ACACACACAC ACACACACAC
4201  ACACACACAC ACACACACAC ACGCCCTACT CTTCATTTGC TAGGGGAAGG
4251  TCACAGCACA ACTAAATCCA GGACAGGACA TTGTGACCAT GACCCAGCCA
4301  CAGTCAATAC CAGAAAGATG ATTCAGAGTC TGAAGTGGTG CCCCAGGTGC
4351  CAACAGGATA ACCTCTACCC CCCGACTTTG TCTCTGGGGT CCTGTTCCTT
4401  CCTGCAAAGC CCAATCCAAG ACTGGCATGG CTCAGAGGTT GTGAGAAAGG
4451  CATGGACTGG AACAATCATG TCCAGAGGGG TCTGGAGCTT TGTTTCCTGT
4501  TCACCAGCAA AAAATGTCTC TCCCATTTTT CTGAAAGTGG CTGATGTAAG
4551  AACAGGCAGA AGGAAAACCC TTTTTGTCAA TAACTCTGTC CTTAAGGAAT
4601  GGTCCTCTGG GAGGGCTGTG CTGCTAGTGG GTACCTCAGT CACACACCCC
4651  CAACCCCAGG CAGCCTCTAG AGCCTTCTTG CTTTCATTTT CCTTGAATGT
4701  ACATAGGAAC AAGGGGGAAA GTCTCTTACT GAAGTGCCTG AAACCCAAAG
4751  CTAGAGCTTC TAGAGACGCC GTTCTTCCTG TCTCAGCTTG GCCAGCCTTT
4801  CAACAATGTT CTCTAGTTTC AAGCTCCAGC TTCTCAGAAA GAATTAAAGA
4851  ACTTGCTGTT CAAATTAAGT AGAAAGTGAG ACTCAATAAT AACTGAACTA
4901  CAGCAAAAGG CAGAGAATTA CAGGGAGAAA AAACTTGTAC TTACCAGCCC
4951  AATTCTACTC TCCTCAAACT GACACACACA CACACACACA CACACACACA
5001  CACACACACA CACACACACT CTTTTAGGGG ACTAAGAGAG AGAAGCATGT
```

```
5051  TATTACATTT TACTCATCCA AACAGTAATG CAAAAATAAA ACGGTAGAAT
5101  ATGAAAAGCT CAGGATCTCT CCCAAGGCTA CCTACTGCAG GAGGGCCAAC
5151  AGGTGAGATG GGAAGAATGG AAACAGGGAC CGATTTTGTA GCTCATACAA
5201  TTAGGACACC TTAGGAATAG CATTGTAGTA ATGGTGATGA ATATGCTCTG
5251  CCAAATTCAT CCAGTCTGCA CCATCTTATA GCTGCCCAGC ACACTCGACT
5301  GTTCATGTGG TCTCTTTGTA GTGTGAGTTT GGAGTGTCCT ATTAGCCTGT
5351  TCTGGTTAGG AATGAGTTAA CGGCTCTTTC CCTCAACCTT AGTCTAGTCC
5401  CAGGGCTGAG GATTCAGCTG GATCCACATG GTCTTGAGGG TTGGCATGAG
5451  GAGGGGGAAG CTTTTTTGAA TCGCTTTTTG ATCACATAAT CTGCCATTTT
5501  AAGAGTAAGA TTTGCTTTAT GGAAATCAAT TCATTAATAA AAAATGATAT
5551  TCAAGTTGCA ATACCATTTC ACAGTGAAAT ATTTTGAGTA CAATTTTGTT
5601  GCTAGAATAG TCATGGGCAA GAGTTTTATG CAAAATGTTT CAATTATGTT
5651  AATAAATAAG ACAATGCWAA AAAAAAAAAA AAAAAAAAAA A
```

Fig. 7: SEQ ID NO. 3

Length: 377 bp

```
  1  CGACTGTTCA TGTGGTCTCT TTGTAGTGTG AGTTTGGAGT GTCCTATTAG
 51  CCTGTTCTGG TTAGGAATGA GTTAACGGCT CTTTCCCTCA ACCTTAGTCT
101  AGTCCCAGGG CTGAGGATTC AGCTGGATCC ACATGGTCTT GAGGGTTGGC
151  ATGAGGAGGG GGAAGCTTTT TTGAATCGCT TTTTGATCAC ATAATCTGCC
201  ATTTTAAGAG TAAGATTTGC TTTATGGAAA TCAATTCATT AATAAAAAAT
251  GATATTCAAG TTGCAATACC ATTTCACAGT GAAATATTTT GAGTACAATT
301  TTGTTGCTAG AATAGTCATG GGCAAGAGTT TTATGCAAAA TGTTTCAATT
351  ATGTTAATAA ATAAGACAAT GCTACAA
```

Fig. 8: Alignment of SEQ ID NO. 3, with human Ensadin-0625 cDNA

Length: 377 bp

```
                .         .         .         .         .
   1 CGACTGTTCATGTGGTCTCTTTGTAGTGTGAGTTTGGAGTGTCCTATTAG 50
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5296 CGACTGTTCATGTGGTCTCTTTGTAGTGTGAGTTTGGAGTGTCCTATTAG 5345
                .         .         .         .         .
  51 CCTGTTCTGGTTAGGAATGAGTTAACGGCTCTTTCCCTCAACCTTAGTCT 100
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5346 CCTGTTCTGGTTAGGAATGAGTTAACGGCTCTTTCCCTCAACCTTAGTCT 5395
                .         .         .         .         .
 101 AGTCCCAGGGCTGAGGATTCAGCTGGATCCACATGGTCTTGAGGGTTGGC 150
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5396 AGTCCCAGGGCTGAGGATTCAGCTGGATCCACATGGTCTTGAGGGTTGGC 5445
                .         .         .         .         .
 151 ATGAGGAGGGGGAAGCTTTTTTGAATCGCTTTTTGATCACATAATCTGCC 200
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5446 ATGAGGAGGGGGAAGCTTTTTTGAATCGCTTTTTGATCACATAATCTGCC 5495
                .         .         .         .         .
 201 ATTTTAAGAGTAAGATTTGCTTTATGGAAATCAATTCATTAATAAAAAAT 250
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5496 ATTTTAAGAGTAAGATTTGCTTTATGGAAATCAATTCATTAATAAAAAAT 5545
                .         .         .         .         .
 251 GATATTCAAGTTGCAATACCATTTCACAGTGAAATATTTTGAGTACAATT 300
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5546 GATATTCAAGTTGCAATACCATTTCACAGTGAAATATTTTGAGTACAATT 5595
                .         .         .         .         .
 301 TTGTTGCTAGAATAGTCATGGGCAAGAGTTTTATGCAAAATGTTTCAATT 350
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5596 TTGTTGCTAGAATAGTCATGGGCAAGAGTTTTATGCAAAATGTTTCAATT 5645
                .         .
 351 ATGTTAATAAATAAGACAATGCTACAA 377
     ||||||||||||||||||||||:| ||
5646 ATGTTAATAAATAAGACAATGCWAAAA 5672
```



Fig. 9: Schematic alignment of SEQ ID NO. 3 with human Ensadin-0625 cDNA

Fig.10

sample	Δ (fold) (temporal / frontal cortex)
control C011	0.84
control C012	0.79
control C014	2.30
control C005	1.13
control C008	0.88
patient P012	0.37
patient P016	0.46
patient P010	1.03
patient P011	0.34
patient P014	0.50
patient P017	0.59
patient P019	0.41



Fig.11

sample	Δ (fold) (hippocampus / frontal cortex)
control C005	0.68
control C008	0.96
control C004	0.82
patient P012	0.50
patient P016	0.36
patient P010	0.15
patient P011	0.38
patient P014	0.78
patient P019	0.51



SEQUENCE LISTING

<110> Evotec NeuroSciences GmbH

<120> Diagnostic and therapeutic use of Ensadin-0625 gene and protein for neurodegenerative disease

<130> 022763ep

<140> 02023272.4
<141> 2002-10-17

<160> 15

<170> PatentIn Ver. 2.1

<210> 1
<211> 307
<212> PRT
<213> Homo sapiens

<400> 1

```
Met Thr Glu Thr Thr Lys Thr His Val Ile Leu Leu Ala Cys Gly Ser
 1               5                  10                  15

Phe Asn Pro Ile Thr Lys Gly His Ile Gln Met Phe Glu Arg Ala Arg
            20                  25                  30

Asp Tyr Leu His Lys Thr Gly Arg Phe Ile Val Ile Gly Gly Ile Val
        35                  40                  45

Ser Pro Val His Asp Ser Tyr Gly Lys Gln Gly Leu Val Ser Ser Arg
    50                  55                  60

His Arg Leu Ile Met Cys Gln Leu Ala Val Gln Asn Ser Asp Trp Ile
65                  70                  75                  80

Arg Val Asp Pro Trp Glu Cys Tyr Gln Asp Thr Trp Gln Thr Thr Cys
                85                  90                  95

Ser Val Leu Glu His His Arg Asp Leu Met Lys Arg Val Thr Gly Cys
            100                 105                 110

Ile Leu Ser Asn Val Asn Thr Pro Ser Met Thr Pro Val Ile Gly Gln
        115                 120                 125

Pro Gln Asn Glu Thr Pro Gln Pro Ile Tyr Gln Asn Ser Asn Val Ala
    130                 135                 140

Thr Lys Pro Thr Ala Ala Lys Ile Leu Gly Lys Val Gly Glu Ser Leu
145                 150                 155                 160

Ser Arg Ile Cys Cys Val Arg Pro Pro Val Glu Arg Phe Thr Phe Val
                165                 170                 175
```

Asp Glu Asn Ala Asn Leu Gly Thr Val Met Arg Tyr Glu Glu Ile Glu
180 185 190

Leu Arg Ile Leu Leu Leu Cys Gly Ser Asp Leu Leu Glu Ser Phe Cys
195 200 205

Ile Pro Gly Leu Trp Asn Glu Ala Asp Met Glu Val Ile Val Gly Asp
210 215 220

Phe Gly Ile Val Val Val Pro Arg Asp Ala Ala Asp Thr Asp Arg Ile
225 230 235 240

Met Asn His Ser Ser Ile Leu Arg Lys Tyr Lys Asn Asn Ile Met Val
245 250 255

Val Lys Asp Asp Ile Asn His Pro Met Ser Val Val Ser Ser Thr Lys
260 265 270

Ser Arg Leu Ala Leu Gln His Gly Asp Gly His Val Val Asp Tyr Leu
275 280 285

Ser Gln Pro Val Ile Asp Tyr Ile Leu Lys Ser Gln Leu Tyr Ile Asn
290 295 300

Ala Ser Gly
305

<210> 2
<211> 5690
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: cDNA sequence
of human Ensadin-0625

<400> 2
atataaactc taaggaagac agtgatggag tgaagtgggc tgggggcgat agagaggatg
60
gggtggggca ccaggcgaga gatgcgaagg aagccagaac gaaaagagag cgaccgagga
120
gagaagagag cagagcaata caaaagcagc ctcggatcta gccggagctg caagcgttaa
180
ggggaggcgg agagtgacgc ggtttgcgtc tggagcggct ccttggagtc cacagcatcc
240
accgccggag cctcgccttc ctttctccct ctgcagacac aacgagacac aaaaagagag
300
gcaaccccta gaccaccgcg aaggacccat ctgcaccatg accgagacca ccaagaccca
360
cgttatcttg ctcgcctgcg gcagcttcaa tcccatcacc aaagggcaca ttcagatgtt
420
tgaaagagcc agggattatc tgcacaaaac tggaaggttt attgtgattg gcgggattgt
480

ctcccctgtc cacgactcct atggaaaaca gggcctcgtg tcaagccggc accgtctcat
540
catgtgtcag ctggccgtcc agaattctga ttggatcagg gtggaccctt gggagtgcta
600
ccaggacacc tggcagacga cctgcagcgt gttggaacac caccgggacc tcatgaagag
660
ggtgactggc tgcatcctct ccaatgtcaa cacaccttcc atgacacctg tgatcggaca
720
gccacaaaac gagacccccc agcccattta ccagaacagc aacgtggcca ccaagcccac
780
tgcagccaag atcttgggga aggtgggaga aagcctcagc cggatctgct gtgtccgccc
840
gccggtggag cgtttcacct ttgtagatga gaatgccaat ctgggcacgg tgatgcggta
900
tgaagagatt gagctacgga tcctgctgct gtgtggtagt gacctgctgg agtccttctg
960
catcccaggg ctctggaacg aggcagatat ggaggtgatt gttggtgact ttgggattgt
1020
ggtggtgccc cgggatgcag ccgacacaga ccgaatcatg aatcactcct caatactccg
1080
caaatacaaa aacaacatca tggtggtgaa ggatgacatc aaccatccca tgtctgttgt
1140
cagctcaacc aagagcaggc tggccctgca gcatggggac ggccatgttg tggattacct
1200
gtcccagccg gtcatcgact acatcctcaa aagccagctg tacatcaatg cctccggcta
1260
gcagcccctc gtcctccggc aacacaatgg cccctccatc tttgtcagcc ccctgtttct
1320
ctcctgcctc tctgtttctc catctcctcg tcttgactgt tttccctact tgctgactta
1380
acccccccata gtgtggggga cctgcagaga accatggcat tccctattcc acagtcatct
1440
ttggacagac tttcctctag tctccgggtt gggggtgggt gagggaatgg ggtgggagtc
1500
gggggaagtg cagtccttgg agatgtactg gtgtccgtct cccagcatgc tctagagagg
1560
cggctctggt gcccatcctc ccagcacgct ctggggaggc ggctctggtg cccatcctcc
1620
cagcatgctc tagagaggcg gctctggtgc ccctcctccc agcatgctct ggggaggcgg
1680
ctctggctct tgccttccca gcatgccctt tactacaaag ggctattttt cttttctttc
1740
ttttgtttat ttatttttct ttgttcactc cctgtagaac ttggatgaaa tcagtgtcca
1800
tggttcttta tgtttgtagt cttgatgtgc tcctgtggta ttacttcccc tctgatagga
1860
cattgtagcc agcctcagca ctcagtgagt tcatcagggc cacacccagt agagaaggcc
1920
aagcaacctc cacttcttca gcaccacaca cacgcacaca cacacacacg cacacatgcg
1980
tgtgcacccg cgcacgcaca tacacacaca catatagcag tagcagcagc agcagcagca
2040
gcagcaacct ttgatcagga gtgagatttt cgggttctga aacctgggac acgagtctgt
2100

gaatagtcgg ttttctcaga ataatttgaa tctgttttct tagtttcaaa tgaccatttc
2160
cctgatgctc tgagcttatg atcacacaga gccagtccat cctcatttcc tggtggcatc
2220
tgttcattta cctttgtgga ctgtagctga tggcacagtg cgggttccct accagccagg
2280
ggtttccaag ggacctttgg aggccatgct tagacacatt cctgtacctg agaacaacca
2340
cataggcagg accagatcca catcgtgcag tcgtgtcata aaaaaacaaa acaaaacaaa
2400
aaaacactag gagtccactc aaccctggag gtctttgcta attggaatta tgtattgtct
2460
gttgggctgg gaaatgtctc tttcatattg taagtccagg atgaactagg agaaagcaat
2520
ttgttgccct gatgataact gatgattttc accctctcta gctgaggtaa ctcagacagt
2580
gcatgaggtc agtttcttct tgagaagcag tgccttggtc ttgtttctgt ggttggttct
2640
agcccctgca gagcctggga gctgcaggaa ctgtctgaga aaatctccct aataggggag
2700
tgggttccca gaagggagat ctgggagggg tcaggagcca ctaagttgct tcactccttt
2760
tttctctaat tttctacctt cctctctgtt cctgcagaca gttttgccag ctttgcttct
2820
ggttactagg gtctcatgcg tgtcctgctt ggagagccat aaggaaattg ctgtcttgtg
2880
ctttgtgtct ctcatccagt ctctggctct tgggattctg gtctttgaga aatagtccct
2940
gagtattagg atacttttat caaaatctag taccagctac ggccagaaag ggccaggtgg
3000
gacctgaaag caaagacaat gttctttacc acacgtttca catctgcaac atccttcaat
3060
tgcgggaaaa ggaacttgat ttaacagaag aacatggtag agcagcatcc agaaagtctg
3120
ttattcctct tggatttttt gaaataatct tcagaggaag gaaggaaaat cctattttgg
3180
ggtatcagtg tttgactagg gatcatgaaa taataaactg aaaaaaactt tagagttcag
3240
ttgatccaac actttccttt aaaagttgag ggagcagagg cccatgggat taaatggctg
3300
gtccaggtca gccagcaggt gtagggcctg acaagaacat attgtttccc tgacccctag
3360
gccgtcacac cacaccctcc atttcctcat gttgctgacc aggtgcccat atgatttcta
3420
cacttcccaa gccttaccct ggcatctttc ttttaaatta tatctgtccc aggtgctctc
3480
cacacatagg atggtaatgc cagtcccagg ggagggtgtg atagtaagga aggccactgt
3540
taggtttcct ttagaaataa agagatctca gcagcttgga agaaatccca gaagcggaac
3600
tccatcaatc caagaaagag ttgctttgtg gaaggtgaag gaagacccac agagtgctca
3660
ggatgatgct attgctggag agcgaaagat ggaacagcct tgtccaggca gaacagtcat
3720

aagccaggaa atgaaacaaa ggaaaacagg tgcctgaatt tcctggggaa acatggcttg
3780
tttaaggact tggagttatg gatggaattt atgggaccca cgtgagcaga cctgaggaag
3840
gctcgatttc ttttgtttct tggtccactc tgtcactctg ctctggtcaa gccccatttg
3900
gtctacagcc catgagaagg aatgaggctg gttctgcact ctcagcatgc agtccgaaag
3960
catgtgggag tggggaggga aagtgagatg aattaagaca aagaacaggt gccatagaag
4020
tagatttcta ggaatgaagt ggggcagatc ttatctttgt ggattacagg cactgtacta
4080
aaaacaggtt tcctatttaa tataaaaaga aagtgaatct tcttttggat agaatcatcc
4140
attcccatcg ccgcaccccc taccccccaa acacacacac acacacacac acacacacac
4200
acacacacac acacacacac acgccctact cttcatttgc taggggaagg tcacagcaca
4260
actaaatcca ggacaggaca ttgtgaccat gacccagcca cagtcaatac cagaaagatg
4320
attcagagtc tgaagtggtg ccccaggtgc caacaggata acctctaccc cccgactttg
4380
tctctggggt cctgttcctt cctgcaaagc ccaatccaag actggcatgg ctcagaggtt
4440
gtgagaaagg catggactgg aacaatcatg tccagagggg tctggagctt tgtttcctgt
4500
tcaccagcaa aaaatgtctc tcccattttt ctgaaagtgg ctgatgtaag aacaggcaga
4560
aggaaaaccc tttttgtcaa taactctgtc cttaaggaat ggtcctctgg gagggctgtg
4620
ctgctagtgg gtacctcagt cacacacccc caaccccagg cagcctctag agccttcttg
4680
ctttcatttt ccttgaatgt acataggaac aaggggggaaa gtctcttact gaagtgcctg
4740
aaacccaaag ctagagcttc tagagacgcc gttcttcctg tctcagcttg gccagccttt
4800
caacaatgtt ctctagtttc aagctccagc ttctcagaaa gaattaaaga acttgctgtt
4860
caaattaagt agaaagtgag actcaataat aactgaacta cagcaaaagg cagagaatta
4920
cagggagaaa aaacttgtac ttaccagccc aattctactc tcctcaaact gacacacaca
4980
cacacacaca cacacacaca cacacacaca cacacacact cttttagggg actaagagag
5040
agaagcatgt tattacattt tactcatcca aacagtaatg caaaaataaa acggtagaat
5100
atgaaaagct caggatctct cccaaggcta cctactgcag gagggccaac aggtgagatg
5160
ggaagaatgg aaacagggac cgattttgta gctcatacaa ttaggacacc ttaggaatag
5220
cattgtagta atggtgatga atatgctctg ccaaattcat ccagtctgca ccatcttata
5280
gctgcccagc acactcgact gttcatgtgg tctctttgta gtgtgagttt ggagtgtcct
5340

attagcctgt tctggttagg aatgagttaa cggctctttc cctcaacctt agtctagtcc
5400
cagggctgag gattcagctg gatccacatg gtcttgaggg ttggcatgag gaggggggaag
5460
ctttttttgaa tcgctttttg atcacataat ctgccatttt aagagtaaga tttgctttat
5520
ggaaatcaat tcattaataa aaaatgatat tcaagttgca ataccatttc acagtgaaat
5580
attttgagta caatttttgtt gctagaatag tcatgggcaa gagttttatg caaaatgttt
5640
caattatgtt aataaataag acaatgcwaa aaaaaaaaaa aaaaaaaaaa
5690

<210> 3
<211> 377
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: cDNA fragment
of the human Ensadin-0625 gene

<400> 3
cgactgttca tgtggtctct ttgtagtgtg agtttggagt gtcctattag cctgttctgg
60
ttaggaatga gttaacggct ctttccctca accttagtct agtcccaggg ctgaggattc
120
agctggatcc acatggtctt gagggttggc atgaggaggg ggaagctttt ttgaatcgct
180
ttttgatcac ataatctgcc attttaagag taagatttgc tttatggaaa tcaattcatt
240
aataaaaaat gatattcaag ttgcaatacc atttcacagt gaaatatttt gagtacaatt
300
ttgttgctag aatagtcatg ggcaagagtt ttatgcaaaa tgtttcaatt atgttaataa
360
ataagacaat gctacaa
377

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
Ensadin-0625 gene

<400> 4
aacggctctt tccctcaacc
20

<210> 5

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the Ensadin-0625 gene

<400> 5
cctcaagacc atgtggatcc a
21

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the cyclophilin B gene

<400> 6
actgaagcac tacgggcctg
20

<210> 7
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the cyclophilin B gene

<400> 7
agccgttggt gtctttgcc
19

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the ribosomal protein S9 gene

<400> 8
ggtcaaattt accctggcca
20

<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the ribosomal protein S9 gene

<400> 9
tctcatcaag cgtcagcagt tc
22

<210> 10
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the beta actin gene

<400> 10
tggaacggtg aaggtgaca
19

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the beta actin gene

<400> 11
ggcaagggac ttcctgtaa
19

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the GAPDH gene

<400> 12
cgtcatgggt gtgaaccatg
20

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the GAPDH gene

<400> 13
gctaagcagt tggtggtgca g
21

<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the transferrin receptor TRR gene

<400> 14
gtcgctggtc agttcgtgat t
21

<210> 15
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the transferrin receptor TRR gene

<400> 15
agcagttggc tgttgtacct ctc
23